ライフサイエンスコーパス: angina

1 mal Medical Therapy of Angioplasty in Stable Angina).

2 h daily or weekly angina as compared with no angina).

3 acute coronary syndromes (including unstable angina).

4 litus, elevated systolic blood pressure, and angina.

5 es and angiographic findings associated with angina.

6 (mortality/MACE) in patients with refractory angina.

7 h, acute MI, or hospitalization for unstable angina.

8 tion including microvascular and vasospastic angina.

9 independently associated with microvascular angina.

10 t correlated with the presence or absence of angina.

11 CI, 0.31-0.88) were associated with unstable angina.

12 oke, coronary revascularization, or unstable angina.

13 ents, given their high prevalence of post-MI angina.

14 o not include subgroup analysis for unstable angina.

15 inical domains beyond the confines of stable angina.

16 a limit their use mostly to the treatment of angina.

17 ncluding 141 MIs and 84 episodes of unstable angina.

18 regarding the use of angiography in unstable angina.

19 w CD133(+) cells in patients with refractory angina.

20 ularization, or hospitalization for unstable angina.

21 alization for progressive angina or unstable angina.

22 Fewer patients underwent PCI for stable angina.

23 e, stroke, unstable angina, and freedom from angina.

24 emic stroke, or hospitalization for unstable angina.

25 na and have been found to improve markers of angina.

26 nt after CTO PCI in patients with refractory angina.

27 For hyperlipidemia (0.14) and angina (0.10), slight agreement was observed.

28 Self-reported angina 1 year after CABG is associated with younger age,

29 c findings are associated with self-reported angina 1 year after CABG.

30 syndrome (myocardial infarction or unstable angina) 1-12 months before randomisation and who had rai

31 .53 to 2.10; p = 0.88) and those with stable angina (11.6% vs. 15.8%; HR: 0.82; 95% CI: 0.50 to 1.343

32 readmission included nonspecific chest pain/angina (24%) and heart failure (11%).

33 Overall, 78 (52%) had isolated microvascular angina, 25 (17%) had isolated vasospastic angina, 31 (20

34 alization, but most (68% of respondents with angina; 27% of the total sample) experienced it less tha

35 (31.9%), non-STEMI type 1 (31.5%), unstable angina (28.5%), and STEMI (8.1%).

36 han 2 out of 5 respondents (44%) experienced angina 30 days after hospitalization, but most (68% of r

37 ar angina, 25 (17%) had isolated vasospastic angina, 31 (20%) had both, and 17 (11%) had noncardiac c

38 domain were compared with patients reporting angina (37.7%).

39 ectively randomized 350 patients with stable angina (55% women; aged 55+/-10 years), mostly with an i

40 Patients reporting no angina (62.3%) within 4 weeks before the 1-year post-CAB

41 atest in PCI procedures performed for stable angina (66%), followed by non-ST-segment-elevation myoca

42 , 3.8% versus 5.9%; P=0.24; and freedom from angina, 93.6% versus 90.2%; P=0.35).

43 S patients (left main stenosis with unstable angina, acute endocarditis, valvular regurgitation with

44 were more likely to be admitted for unstable angina (adjusted OR, 1.46 [95% CI, 1.04-2.05]).

45 infarction, and nonfatal stroke) and 1-year angina after CABG and PCI using baseline covariates and

46 ic and clinical factors were associated with angina after CABG: younger age, worse preoperative SAQ a

47 associate with a diagnosis of microvascular angina although this was not significant (OR, 2.7 [0.9-7

48 on acute coronary syndromes (MI and unstable angina) among IRIS participants.

49 with higher scores indicating less frequent angina and better function and quality of life).

50 randomly assigning 918 patients with typical angina and either two or more cardiovascular risk factor

51 e a novel potential treatment for refractory angina and have been found to improve markers of angina.

52 Ranolazine both treats chronic angina and improves glucose control.

53 l trial in which 2,604 patients with chronic angina and incomplete revascularization following percut

54 Likewise, clinical scenarios with unstable angina and intermediate- or high-risk features were deem

55 The mechanisms governing exercise-induced angina and its alleviation by the most commonly used ant

56 wn about race and sex differences in post-MI angina and long-term risk of unplanned rehospitalization

57 tients with diabetes mellitus (DM) have less angina and more silent ischemia when compared with those

58 on acute coronary syndromes include unstable angina and non-ST-segment elevation myocardial infarctio

59 Patients with angina and nonobstructive coronary artery disease had si

60 Patients with angina and nonobstructive coronary artery disease underw

61 In patients with angina and nonobstructive coronary artery disease, dimin

62 Among patients with angina and nonobstructive coronary artery disease, those

63 e study, both in the placebo group (unstable angina and pneumonia).

64 s for the evaluation of patients with stable angina and public policy.

65 tion was observed with respect to changes in angina and quality of life, cumulative diagnostic costs,

66 Among patients with stable angina and risk factors for coronary artery disease, myo

67 RETATION: In patients with medically treated angina and severe coronary stenosis, PCI did not increas

68 elevation acute coronary syndromes or stable angina and to evaluate long-term outcomes of nonenrolled

69 tor dysfunction is frequent in patients with angina and unobstructed coronaries in a European populat

70 Microvascular angina and vasospastic angina are distinct disorders tha

71 -elevation myocardial infarction or unstable angina) and stable presentation (51% stable angina or at

72 ularization, or hospitalization for unstable angina) and total key secondary composite endpoint event

73 infarction, or hospitalization for unstable angina), and healthcare expenditures.

74 revention strategies and treatment of stable angina), and in the selection of revascularization strat

75 rction (MI), heart failure, stroke, unstable angina, and freedom from angina.

76 atal stroke, hospital admission for unstable angina, and hospital admission for heart failure, analys

77 th escalation included lung disease, ongoing angina, and periprocedural major adverse cardiac and cer

78 e (fatal and nonfatal myocardial infarction, angina, and stroke) and type 2 diabetes costs associated

79 ions for percutaneous coronary intervention, angina, and stroke.

80 w tract obstruction and symptoms of dyspnea, angina, and syncope.

81 pooled were MACE, mortality, and indices of angina (angina episodes, Canadian Cardiovascular Society

82 Microvascular angina and vasospastic angina are distinct disorders that may coexist but diffe

83 RATIONALE: New therapies for refractory angina are needed.

84 sease (CVD) (myocardial infarction, unstable angina, arterial revascularization, stroke, or cardiovas

85 nths among participants with daily or weekly angina as compared with no angina).

86 ifestations (myocardial infarction, unstable angina) as secondary outcomes.

87 emic stroke, or hospitalization for unstable angina-as well as total nonfatal cardiovascular events a

88 Further, only 30.6% of subjects reporting angina at 1 year had a residual major coronary artery st

89 in 346 (18.2%) patients, and 310 (16.3%) had angina at 1 year.

90 The percentage of patients free from angina at 12 months did not differ significantly between

91 , ranolazine's effect on glucose control and angina at 6 months was proportionate to baseline HbA1c,

92 nts, black patients were more likely to have angina at 6 weeks (female: 44.2% versus 31.8%; male: 33.

93 6.2), and nearly absent among those without angina at baseline (0.6 points; 95% credible interval, -

94 gest among participants with daily or weekly angina at baseline (10.1 points; 95% credible interval,

95 0 to 19.9), smaller among those with monthly angina at baseline (2.2 points; 95% credible interval, -

96 ger among participants who had more frequent angina at baseline (8.5 vs. 0.1 points at 3 months and 5

97 ntal stress is independently associated with angina at baseline and during follow-up.

98 , which included 35% of participants without angina at baseline, patients randomly assigned to the in

99 arger differences among patients who had had angina at baseline.

100 nd unstable angina with greater freedom from angina at the expense of higher rates of procedural MI.

101 c death, MI, unstable angina, or progressive angina) at latest follow-up.

102 gistry, refractory angina was defined as any angina (baseline Seattle Angina Questionnaire [SAQ] Angi

103 ND In a 10-site US PCI registry, we assessed angina before and at 1, 6, and 12 months after elective

104 These patients have comparable angina burden but reduced quality of life compared to pa

105 A total of 86 patients with angina but no obstructive coronary disease underwent cor

106 The classic presenting symptom of SIHD is angina, but clinical presentation varies greatly among p

107 rction (MI), or hospitalization for unstable angina by 1 year.

108 medical treatment; (3) patients had ongoing angina, Canadian Cardiovascular Society class II-IV; and

109 In addition to improvements in indices of angina, cell-based therapies improve cardiovascular outc

110 ian-assessed Canadian Cardiovascular Society angina class (P(interaction)=0.693), and treadmill exerc

111 Health status (EuroQol 5 Dimensions) and angina class in each group were similar at 12 months.

112 na episodes, Canadian Cardiovascular Society angina class, exercise tolerance, and antianginal medica

113 for nonfatal myocardial infarction, unstable angina, congestive heart failure, emergency coronary rev

114 Patients with typical angina decreased, whereas patients with dyspnea and atyp

115 urrent Canadian Cardiovascular Society II-IV angina, despite optimal medical therapy, >/=1 myocardial

116 ormed in individuals free from CAD or stable angina diagnosis.

117 tionate to baseline HbA1c, but the effect on angina dissipated by 12 months.

118 In patients who were not diagnosed with angina due to coronary heart disease, coronary CTA was a

119 early half the participants (49%) had had no angina during the month before randomization.

120 were MACE, mortality, and indices of angina (angina episodes, Canadian Cardiovascular Society angina

121 Dyspnea is a common angina equivalent that adversely affects quality of life

122 Patients with refractory angina experienced large, clinically significant health

123 or revascularization, hypertension, unstable angina, female sex, nonwhite race, and US location were

124 edian (interquartile range [IQR]) scores for angina frequency (100.0 [80.0-100.0]) overall with simil

125 A similar pattern was noted for SAQ angina frequency (mean change 24.0+/-27.2 versus 18.7+/-

126 to DES-PCI on several SAQ domains including angina frequency and physical function, as well as the r

127 Older respondents had more angina frequency and physical limitations and lower trea

128 ficantly larger degree of improvement of SAQ Angina Frequency and SAQ Summary Score (35.0+/-26.8 vers

129 the 1-year post-CABG study visit on the SAQ angina frequency domain were compared with patients repo

130 tempt using the Seattle Angina Questionnaire Angina Frequency domain.

131 highly symptomatic at baseline with mean SAQ Angina Frequency of 51.1+/-23.8, SAQ quality of life of

132 ve PCI with the Seattle Angina Questionnaire angina frequency score (range, 0-100, higher=better).

133 once per week (Seattle Angina Questionnaire angina frequency score 60).

134 (baseline Seattle Angina Questionnaire [SAQ] Angina Frequency score of <=90) despite treatment with >

135 ocardiography score and the effect of PCI on angina frequency score with a larger placebo-controlled

136 er CABG: younger age, worse preoperative SAQ angina frequency score, smoking, diabetes mellitus, and

137 ociated with younger age, worse baseline SAQ angina frequency score, smoking, diabetes mellitus, and

138 ssed with the Seattle Angina Questionnaire's angina frequency subscale at baseline and 2 years follow

139 ing in the inferior frontal lobe activation, angina frequency was increased by 13.7 units at baseline

140 The reductions in angina frequency were numerically greater among patients

141 ntrolled efficacy of PCI on patient-reported angina frequency.

142 overall population and according to baseline angina frequency.

143 vention (PCI) among patients with refractory angina has not been reported.

144 h, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI int

145 condary outcomes were myocardial infarction, angina, heart failure, hypertension, arrhythmias, arteri

146 infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest.

147 infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest.

148 atal stroke, hospital admission for unstable angina, hospital admission for heart failure, or impaire

149 choline was associated with higher hazard of angina hospitalization (HR: 1.05; 95% CI: 1.02 to 1.07;

150 nonfatal myocardial infarction, and unstable angina hospitalization was similar and fair for both CAC

151 as death, myocardial infarction, or unstable angina hospitalizations over a median follow-up of 26.1

152 infarction, stroke, and heart failure), and angina hospitalizations served as clinical outcomes over

153 n of this region with stress correlates with angina in individuals with coronary artery disease.

154 correlates of microvascular and vasospastic angina in patients with symptoms and signs of ischemia b

155 or dysfunction is an important mechanism for angina in patients with unobstructed coronary arteries.

156 ion is increasingly recognized as a cause of angina in pulmonary arterial hypertension (PAH).

157 baseline, 35% of patients reported having no angina in the previous month.

158 fect of angiography on mortality in unstable angina, incorporating the results of additional cardiac

159 , whereas patients with dyspnea and atypical angina increased.

160 Angina, initial shockable rhythm, ST-segment elevation,

161 of LMCA compression in patients with PAH and angina is high.

162 oke, coronary revascularisation, or unstable angina; key secondary endpoint was the composite of card

163 ction, stroke, or urgent hospitalization for angina leading to coronary revascularization.

164 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization.

165 All patients with PAH and angina or angina-like symptoms attending the center between May 1,

166 tery (PA) in patients with PAH and angina or angina-like symptoms, determine the usefulness of screen

167 indicated in patients with PAH and angina or angina-like symptoms.

168 Better treatment of post-MI angina may improve patient quality of life and quality o

169 Angina might persist or reoccur despite successful revas

170 The 6-variable angina model included a treatment interaction with SYNTA

171 We examined the risk of unstable angina, myocardial infarction, coronary revascularizatio

172 ith no evidence for pooled associations with angina, myocardial infarction, heart failure, or stroke.

173 y, rehospitalization for refractory ischemia/angina, myocardial infarction, hospitalization because o

174 stroke n = 4; RR, 1.17; 95% CI, 1.14-1.20), angina (n = 2; RR, 1.18; 95% CI, 1.13-1.24), and heart f

175 Emergently admitted patients with unstable angina (n = 33 901) who did or did not receive angiograp

176 ocardial infarction (n = 4; 13.8%), unstable angina (n = 8; 27.6%), congestive heart failure exacerba

177 te consisting of myocardial infarction (MI), angina, need for coronary revascularization, and cardiac

178 outcome consisting of myocardial infarction, angina, need for coronary revascularization, stroke, or

179 ients were older than 18 years with unstable angina, non-ST segment elevation myocardial infarction (

180 symptoms (congestive heart failure, unstable angina, non-ST-elevation myocardial infarction, syncope)

181 nt treadmill MPS (n=4764), only 27% reported angina on the treadmill.

182 coronary syndrome and 369 [27.2%] for stable angina) on patients admitted to nonintensive care unit w

183 re were three adverse events (one episode of angina, one fall during a multifactorial fall-prevention

184 chest pain, hospital admission for unstable angina or acute myocardial infarction [AMI], 30-day read

185 A total of 2037 participants with stable angina or an acute coronary syndrome who had an indicati

186 Among patients with stable angina or an acute coronary syndrome, an iFR-guided reva

187 All patients with PAH and angina or angina-like symptoms attending the center betw

188 lmonary artery (PA) in patients with PAH and angina or angina-like symptoms, determine the usefulness

189 t CTCA is indicated in patients with PAH and angina or angina-like symptoms.

190 angina) and stable presentation (51% stable angina or atypical symptoms).

191 nd 6 hours with no evidence of preinfarction angina or collateral blood flow.

192 years, history of heart disease, symptoms of angina or dyspnea, hemoglobin <12 mg/dl, vascular surger

193 for stable angina or urgent PCI for unstable angina or non-ST segment elevation myocardial infarction

194 High-risk patients with unstable angina or non-ST-segment-elevation myocardial infarction

195 ul PCI, does not influence the recurrence of angina or the outcome; these findings should be taken in

196 ization or rehospitalization for progressive angina or unstable angina.

197 s and had had either elective PCI for stable angina or urgent PCI for unstable angina or non-ST segme

198 7.5 [95% CI, 1.7-33.0]; P=0.008) and typical angina (OR, 2.7 [1.1-6.6]; P=0.032) were independently a

199 ry heart disease (including heart attack and angina) or stroke (including ischaemic stroke or haemorr

200 rction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary en

201 ion, stroke, hospital admission for unstable angina, or coronary revascularization.

202 rction, stroke, hospitalization for unstable angina, or coronary revascularization.

203 atal stroke, hospital admission for unstable angina, or hospital admission for heart failure.

204 infarction (MI), stroke, revascularization, angina, or ischemic electrocardiogram) was associated wi

205 cardiac events (cardiac death, MI, unstable angina, or progressive angina) at latest follow-up.

206 ed by death, myocardial infarction, unstable angina, or urgent coronary revascularization.

207 nt-reported response variables: freedom from angina (P(interaction)=0.116), physical limitation (P(in

208 y (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Imp

209 In biomarker-negative stable and unstable angina patients undergoing elective PCI, the trial did n

210 Refractory angina patients were highly symptomatic at baseline with

211 nt cohorts of patients with suspected stable angina pectoris (SAP) (3033 patients; median 10.7 y foll

212 75 in the best available therapy group) and angina pectoris (two [3%] of 74 in the ruxolitinib group

213 t-elevation myocardial infarction and stable angina pectoris , similar patterns were found albeit les

214 The use of nitroglycerin in the treatment of angina pectoris began not long after its original synthe

215 h Canadian Cardiovascular Society grading of angina pectoris class 1 (n=1107, 18 events).

216 h Canadian Cardiovascular Society grading of angina pectoris class 2 or higher (n=839, 34 events), in

217 AxCanadian Cardiovascular Society grading of angina pectoris class interaction was observed in SCD ri

218 , Canadian Cardiovascular Society grading of angina pectoris class, and exercise capacity were used a

219 Angina pectoris during RCA occlusion tended to occur in

220 intracoronary ECG ST-segment elevation, and angina pectoris during the same 1-minute coronary occlus

221 CI (with or without FFR guidance) for stable angina pectoris in Sweden between January 2005 and March

222 vascular and cerebrovascular diseases (e.g., angina pectoris, heart failure, cerebral infarction).

223 t CVD, defined as new myocardial infarction, angina pectoris, or stroke, which developed between base

224 rm clinical outcomes in patients with stable angina pectoris.

225 s prognostic benefit in patients with stable angina pectoris.

226 enosis in patients undergoing PCI for stable angina pectoris.

227 al, 23,860 patients underwent PCI for stable angina pectoris; of these, FFR guidance was used in 3,36

228 rtery disease, history of stable or unstable angina, previous multi-vessel percutaneous coronary inte

229 f-reported angina symptoms using the Seattle Angina Questionnaire (SAQ) and angiographic findings aft

230 , 12, 36, and 60 months by using the Seattle Angina Questionnaire (SAQ) and the 36-Item Short Form He

231 nction, and quality of life with the Seattle Angina Questionnaire (SAQ) at randomization, at months 1

232 We assessed health status with the Seattle Angina Questionnaire (SAQ) before randomization and at 1

233 orted health status, assessed by the Seattle Angina Questionnaire (SAQ), were compared across appropr

234 was defined as any angina (baseline Seattle Angina Questionnaire [SAQ] Angina Frequency score of <=9

235 translated, validated version of the Seattle Angina Questionnaire administered 30 days after discharg

236 the index CTO PCI attempt using the Seattle Angina Questionnaire Angina Frequency domain.

237 2 months after elective PCI with the Seattle Angina Questionnaire angina frequency score (range, 0-10

238 erienced it less than once per week (Seattle Angina Questionnaire angina frequency score 60).

239 independently associated with poorer Seattle Angina Questionnaire summary scores at 1-year (beta esti

240 Angina was assessed with the Seattle Angina Questionnaire's angina frequency subscale at base

241 bjects had similar burden of angina (Seattle Angina Questionnaire) but reduced quality of life compar

242 e assessed with the disease-specific Seattle Angina Questionnaire, and 5-year mortality was assessed

243 e and 1, 12, and 36 months using the Seattle Angina Questionnaire, the 12-Item Short Form Health Surv

244 ts including coronary insufficiency/unstable angina, recognized myocardial infarction, coronary revas

245 major acute cardiovascular events (MACE) and angina reduction.

246 condary objective of the trial was to assess angina-related health status among these patients.

247 invasive strategy had greater improvement in angina-related health status than those assigned to the

248 tantial or sustained benefits with regard to angina-related health status with an initially invasive

249 condary objective of the trial was to assess angina-related health status.

250 We assessed angina-related symptoms, function, and quality of life w

251 trial of PCI versus a placebo procedure for angina relief that was done at five study sites in the U

252 In general, CABG resulted in greater angina relief, although the absolute treatment benefit w

253 nginal drug; or recurrence or persistence of angina requiring a coronary angiography.

254 cardiac event; recurrence or persistence of angina requiring an addition, switch, or increase of the

255 eath, myocardial infarction (MI), refractory angina requiring coronary revascularization, and ischemi

256 l or non-fatal ischaemic stroke, or unstable angina requiring hospital admission.

257 ial infarction, ischemic stroke, or unstable angina requiring hospitalization.

258 tal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.

259 oke, coronary revascularization, or unstable angina requiring hospitalization.

260 ial infarction, ischemic stroke, or unstable angina requiring hospitalization.

261 A significant reduction in unstable angina (RR, 0.64 [95% CI, 0.45-0.92]) and increase in fr

262 CI, 0.45-0.92]) and increase in freedom from angina (RR, 1.10 [95% CI, 1.05-1.15]) was also observed

263 INOCA subjects had similar burden of angina (Seattle Angina Questionnaire) but reduced qualit

264 d to subgroups of patients with unacceptable angina, severe left ventricular systolic dysfunction, or

265 ffect of inferior frontal lobe activation on angina severity, respectively.

266 ated clinical characteristics, symptoms, and angina severity.

267 As they developed limiting angina, sublingual nitroglycerin was administered to hal

268 PCI with stenting, of whom 41 had sustained angina symptom relief.

269 nseling patients on expected improvements in angina symptoms and in making decisions regarding the ne

270 nt of these comorbidities improves post-CABG angina symptoms requires further study.

271 D Patients referred for evaluation of stable angina symptoms underwent adenosine-stress dynamic compu

272 e relationship between patient self-reported angina symptoms using the Seattle Angina Questionnaire (

273 Angina symptoms were also better controlled in the exper

274 ore unblinding, hospitalization for unstable angina that led to urgent revascularization was added to

275 levation myocardial infarction, and unstable angina) to compare rates of cardiac procedures (Catheter

276 In patients with stable angina, two strategies are often used to guide revascula

277 Angina typicality was determined using standard criteria

278 grel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) myocardia

279 The secondary endpoint was MACE + unstable angina (UA) receiving early (<=24 h) revascularization.

280 all-cause mortality in patients with stable angina undergoing PCI.

281 luded 1,379 consecutive patients with stable angina, unobstructed coronaries and ACH test performed f

282 aphy within 2 months of their index unstable angina versus 0.097 (CI, 0.090 to 0.105) for those not r

283 he only angiographic finding associated with angina was a poorly revascularized LAD territory.

284 Angina was assessed 6 months after the index CTO PCI att

285 Angina was assessed with the Seattle Angina Questionnair

286 Vasospastic angina was associated with smoking (OR, 9.5 [2.8-32.7];

287 Typical angina was associated with the highest prevalence for po

288 CTO PCI in a 12-center registry, refractory angina was defined as any angina (baseline Seattle Angin

289 raphic finding significantly associated with angina was incomplete revascularization of the left ante

290 Refractory angina was present at baseline in 148 patients (14.8%).

291 Refractory angina was present in 1 of 7 patients in the OPEN-CTO (O

292 Angina was significantly less severe in the PCI group at

293 emic stroke, or hospitalization for unstable angina) was examined according to American College of Ca

294 Three hundred ninety-one patients with angina were enrolled at 2 regional centers over 12 month

295 l infarction, and were not being treated for angina were randomly assigned to atorvastatin 10 mg dail

296 s, high blood pressure, high cholesterol and angina) were quantified with logistic regression models

297 lower risk of nonprocedural MI and unstable angina with greater freedom from angina at the expense o

298 In patients with DM and chronic angina with incomplete revascularization after percutane

299 cular death, myocardial infarction, unstable angina with revascularization, and heart failure hospita

300 th systolic heart failure and chronic stable angina without clinically significant adverse effects.